This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2004, p. 2149-2152, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2149-2152.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp.

Ellie J. C. Goldstein,1,2* Diane M. Citron,1 C. Vreni Merriam,1 Yumi A. Warren,1 Kerin L. Tyrrell,1 and Helen T. Fernandez1

R. M. Alden Research Laboratory, Santa Monica, California 90404,1 UCLA School of Medicine, Los Angeles, California 900732

Received 16 October 2003/ Returned for modification 21 January 2004/ Accepted 9 February 2004

Telavancin is a new semisynthetic glycopeptide anti-infective with multiple mechanisms of action, including inhibition of bacterial membrane phospholipid synthesis and inhibition of bacterial cell wall synthesis. We determined the in vitro activities of telavancin, vancomycin, daptomycin, linezolid, quinupristin-dalfopristin, imipenem, piperacillin-tazobactam, and ampicillin against 268 clinical isolates of anaerobic gram-positive organisms and 31 Corynebacterium strains using agar dilution methods according to National Committee for Clinical Laboratory Standards procedures. Plates with daptomycin were supplemented with Ca2+ to 50 mg/liter. The MICs at which 90% of isolates tested were inhibited (MIC90s) for telavancin and vancomycin were as follows: Actinomyces spp. (n = 45), 0.25 and 1 µg/ml, respectively; Clostridium difficile (n = 14), 0.25 and 1 µg/ml, respectively; Clostridium ramosum (n = 16), 1 and 4 µg/ml, respectively; Clostridium innocuum (n = 15), 4 and 16 µg/ml, respectively; Clostridium clostridioforme (n = 15), 8 and 1 µg/ml, respectively; Eubacterium group (n = 33), 0.25 and 2 µg/ml, respectively; Lactobacillus spp. (n = 26), 0.5 and 4 µg/ml, respectively; Propionibacterium spp. (n = 34), 0.125 and 0.5 µg/ml, respectively; Peptostreptococcus spp. (n = 52), 0.125 and 0.5 µg/ml, respectively; and Corynebacterium spp. (n = 31), 0.03 and 0.5 µg/ml, respectively. The activity of TD-6424 was similar to that of quinupristin-dalfopristin for most strains except C. clostridioforme and Lactobacillus casei, where quinupristin-dalfopristin was three- to fivefold more active. Daptomycin had decreased activity (MIC > 4 µg/ml) against 14 strains of Actinomyces spp. and all C. ramosum, Eubacterium lentum, and Lactobacillus plantarum strains. Linezolid showed decreased activity (MIC > 4 µg/ml) against C. ramosum, two strains of C. difficile, and 15 strains of Lactobacillus spp. Imipenem and piperacillin-tazobactam were active against >98% of strains. The MICs of ampicillin for eight Clostridium spp. and three strains of L. casei were >1 µg/ml. The MIC90 of TD-6424 for all strains tested was <=2 µg/ml. TD-6424 has potential for use against infections with gram-positive anaerobes and deserves further clinical evaluation.

* Corresponding author. Mailing address: R. M. Alden Research Laboratory, 2021 Santa Monica Blvd., Suite 740 East, Santa Monica, CA 90404. Phone: (310) 315-1511. Fax: (310) 315-3662. E-mail: EJCGMD{at}aol.com.

Antimicrobial Agents and Chemotherapy, June 2004, p. 2149-2152, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2149-2152.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Finegold, S. M., Bolanos, M., Sumannen, P. H., Molitoris, D. R. (2009). In Vitro Activities of Telavancin and Six Comparator Agents against Anaerobic Bacterial Isolates. Antimicrob. Agents Chemother. 53: 3996-4001 [Abstract] [Full Text]  
  • Schoen, C., Unzicker, C., Stuhler, G., Elias, J., Einsele, H., Grigoleit, G. U., Abele-Horn, M., Mielke, S. (2009). Life-Threatening Infection Caused by Daptomycin-Resistant Corynebacterium jeikeium in a Neutropenic Patient. J. Clin. Microbiol. 47: 2328-2331 [Abstract] [Full Text]  
  • Leonard, S. N., Vidaillac, C., Rybak, M. J. (2009). Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 53: 2928-2933 [Abstract] [Full Text]  
  • Charneski, L., Patel, P. N, Sym, D. (2009). Telavancin: A Novel Lipoglycopeptide Antibiotic. The Annals of Pharmacotherapy 43: 928-938 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 62: 116-121 [Abstract] [Full Text]  
  • Krause, K. M., Renelli, M., Difuntorum, S., Wu, T. X., Debabov, D. V., Benton, B. M. (2008). In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria. Antimicrob. Agents Chemother. 52: 2647-2652 [Abstract] [Full Text]  
  • Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States. Antimicrob. Agents Chemother. 52: 2383-2388 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Jansen, W. T. M., Verel, A., Verhoef, J., Milatovic, D. (2007). In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe. Antimicrob. Agents Chemother. 51: 3420-3424 [Abstract] [Full Text]  
  • Odenholt, I., Lowdin, E., Cars, O. (2007). Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic Model. Antimicrob. Agents Chemother. 51: 3311-3316 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., de-Lazzari, E., Soy, D., Moreno, A., del Rio, A., Almela, M., Mestres, C. A., Gatell, J. M., Jimenez-de-Anta, M.-T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2007). Efficacy of Telavancin in the Treatment of Experimental Endocarditis Due to Glycopeptide-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 2373-2377 [Abstract] [Full Text]  
  • Sun, H. K., Duchin, K., Nightingale, C. H., Shaw, J.-P., Seroogy, J., Nicolau, D. P. (2006). Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects. Antimicrob. Agents Chemother. 50: 788-790 [Abstract] [Full Text]  
  • Shah, M., Murillo, J. L (2005). Successful Treatment of Corynebacterium striatum Endocarditis with Daptomycin plus Rifampin. The Annals of Pharmacotherapy 39: 1741-1743 [Abstract] [Full Text]  
  • Higgins, D. L., Chang, R., Debabov, D. V., Leung, J., Wu, T., Krause, K. M., Sandvik, E., Hubbard, J. M., Kaniga, K., Schmidt, D. E. Jr., Gao, Q., Cass, R. T., Karr, D. E., Benton, B. M., Humphrey, P. P. (2005). Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 1127-1134 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»